Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study.

FIGURE 2 | Isolates expressing serotypes present in PPV23 but not included in conjugate vaccines causing invasive pneumococcal disease in adult patients ( ≥ 18 years) in

This is a prospective, case-series, laboratory-surveillance study, whose laboratory data of serotyping and in vitro susceptibility to antimicrobial agents of invasive

Poliomyelitis immunity (serotypes 1, 2 and 3 anti-polio antibodies) was highly prevalent (>90%) in a representative population of São Paulo, Brazil, which is in accordance with

Invasive pneumococcal disease causes high morbidity and mortality, especially in at-risk patients and older adults, as well as having a higher incidence in patients with

Glycoconjugate vaccines against meningococcal Group C and against seven pneumococcal serotypes have been licensed, whilst glycoconjugate vaccines against other meningococcal CPSs,

In Brazil, however, there is just one conjugated pneumococcal vaccine, the 7-valent vaccine conjugated with the CRM197 diphtheria toxin (serotypes 4, 6B, 9V, 14, 18C, 19F and

Objectives: To identify the most common pneumococcal serotypes in children hospitalized with invasive pneumonia, correlate isolated serotypes with those included

Invasive pneumococcal disease causes high morbidity and mortality, especially in at-risk patients and older adults, as well as having a higher incidence in patients with